- Home
- QCRH vs GPCR Comparison
QCRH vs GPCR Comparison
Compare QCRH & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- GPCR
- Stock Information
- Founded
- QCRH 1993
- GPCR 2016
- Country
- QCRH United States
- GPCR United States
- Employees
- QCRH N/A
- GPCR N/A
- Industry
- QCRH Major Banks
- GPCR
- Sector
- QCRH Finance
- GPCR
- Exchange
- QCRH Nasdaq
- GPCR Nasdaq
- Market Cap
- QCRH 1.1B
- GPCR 1.1B
- IPO Year
- QCRH 1993
- GPCR 2023
- Fundamental
- Price
- QCRH $70.01
- GPCR $17.59
- Analyst Decision
- QCRH Buy
- GPCR Strong Buy
- Analyst Count
- QCRH 3
- GPCR 7
- Target Price
- QCRH $88.83
- GPCR $76.17
- AVG Volume (30 Days)
- QCRH 123.6K
- GPCR 734.9K
- Earning Date
- QCRH 07-23-2025
- GPCR 08-11-2025
- Dividend Yield
- QCRH 0.34%
- GPCR N/A
- EPS Growth
- QCRH N/A
- GPCR N/A
- EPS
- QCRH 6.63
- GPCR N/A
- Revenue
- QCRH $322,873,000.00
- GPCR N/A
- Revenue This Year
- QCRH N/A
- GPCR N/A
- Revenue Next Year
- QCRH $6.82
- GPCR N/A
- P/E Ratio
- QCRH $10.61
- GPCR N/A
- Revenue Growth
- QCRH N/A
- GPCR N/A
- 52 Week Low
- QCRH $60.83
- GPCR $13.22
- 52 Week High
- QCRH $96.08
- GPCR $45.37
- Technical
- Relative Strength Index (RSI)
- QCRH 41.62
- GPCR 31.53
- Support Level
- QCRH $73.32
- GPCR $17.45
- Resistance Level
- QCRH $76.49
- GPCR $18.78
- Average True Range (ATR)
- QCRH 2.02
- GPCR 0.82
- MACD
- QCRH -0.70
- GPCR 0.00
- Stochastic Oscillator
- QCRH 5.54
- GPCR 5.00
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.